In a report released today, Robert Wasserman from Benchmark Co. maintained a Buy rating on Nephros, with a price target of $5.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Robert Wasserman’s rating is based on Nephros’s impressive financial performance in the second quarter of 2025, where the company exceeded expectations with a significant increase in revenue and a shift to positive net income. The revenue growth was driven by strong programmatic sales and a substantial order in dialysis filtration, alongside an expansion in active user sites.
Additionally, Nephros has successfully launched new products and expanded its market reach beyond hospitals, contributing to its sales growth. The company also reported improved gross margins and a rise in adjusted EBITDA, strengthening its cash position with no long-term debt. These factors, combined with anticipated revenue growth, support the maintained Speculative Buy rating and a price target that suggests potential price appreciation.
In another report released on August 8, Maxim Group also maintained a Buy rating on the stock with a $6.00 price target.